KWM
XERS icon

Kingsview Wealth Management’s Xeris Biopharma Holdings XERS Stock Holding History

Kingsview Wealth Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.2K Hold
10,000
– – ﹤0.01% 1399
2026
Q1 		$58K Hold
10,000
– – ﹤0.01% 1307
2025
Q4 		$78.5K Buy
+10,000
New +$78.7K ﹤0.01% 1217

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Kingsview Wealth Management's XERS Position: Q2 2026 in Review

Kingsview Wealth Management held its Xeris Biopharma Holdings (XERS) position steady in Q2 2026 at 10,000 shares worth $79.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1399.

Kingsview Wealth Management first reported a position in XERS in Q4 2025 and has held it in 3 quarters since. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Kingsview Wealth Management held 10,000 shares of Xeris Biopharma Holdings worth $79.2K as of Q2 2026.
  • Kingsview Wealth Management left its Xeris Biopharma Holdings share count unchanged in Q2 2026.
  • Xeris Biopharma Holdings made up ﹤0.01% of Kingsview Wealth Management's portfolio in Q2 2026, its #1399 holding.
  • Kingsview Wealth Management first reported a position in Xeris Biopharma Holdings in Q4 2025 and has held it in 3 quarters since.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.